a public good project by the
Synthesis
Company
of California

© 2026

P. Richard Harrigan | doi.page

0 works0 citations0 h-index

P. Richard Harrigan

Intellicell Biosciences (United States)(US)

Publications by Year

Research Areas

HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, Hepatitis C virus research, HIV-related health complications and treatments

Most-Cited Works

→ Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study(2010)778 cited
→ Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy(1995)634 cited
→ Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients(2002)572 cited
→ The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic(2006)551 cited
→ Adaptation of HIV-1 to human leukocyte antigen class I(2009)467 cited
→ Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy(2005)434 cited

→ Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/L(2003)

362 cited

→ Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The “HIV Treatment as Prevention” Experience in a Canadian Setting(2014)357 cited

→ Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration(2005)318 cited

→ Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness(2006)315 cited